Efficacy and cost-effectiveness of consensus interferon monotherapy with high-dose induction for hepatitis C patients with genotype 2

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 1, 2011, Pages 79-90

  Iwasaki, Yoshiaki ^a   Tanaka, Hironori ^a,k,m   Ikeada, Hiroshi ^b   Okamoto, Ryo Ichi ^c   Araki, Yasuyuki ^c   Yabushita, Kazuhisa ^d   Kobashi, Haruhiko ^a,e   Kariyama, Kazuya ^f   Kawaguchi, Mitsuhiko ^g   Takaguchi, Kouichi ^h   Sakata, Tatsuro ⁱ   Ando, Masaharu ^j   Sakaguchi, Kohsaku ^a,d   Aoki, Noriaki ^l,m   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KURASHIKI CENTRAL HOSPITAL   (Japan)

^c HIROSHIMA CITY HOSPITAL   (Japan)

^d Fukuyama City Hospital   (Japan)

^e Tsuyama Central Hospital   (Japan)

^f Okayama Citizens Hospital   (Japan)

^g OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^h KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION FUKUYAMA MEDICAL CENTER   (Japan)

^j Japan   (Japan)

^k HYOGO COLLEGE OF MEDICINE   (Japan)

^l Outcomes Research and Development Japan CHORD J   (Japan)

^m University of Texas School of Health Information Sciences at Houston   (United States)

more..

Author keywords

Chronic hepatitis C; Consensus interferon; Cost effectiveness; Genotype 2; High dose induction

Indexed keywords

ALPHA2B INTERFERON; CONSENSUS INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; VISUAL DISORDER;

COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 78651356512     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.516449     Document Type: Article

References (46)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N EnglJ Med 2001;345:41-52.
2. Dienstag JL, McHutchison JG. American Gastroenterolog-ical Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-64.
3. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
4. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-71.
5. Fattovich G, Zagni I, Minola E, Felder M, Rovere P, Carlotto A, et al. A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J Hepatol 2003;39:843-9.
6. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-43.
7. Jensen DM, Krawitt EL, Keeffe EB, Hollinger FB, James SP, Mullen K, et al. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus Interferon Study Group. Am J Gastroenterol 1999;94: 3583-8.
8. Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepa-tology 1997;26:101S-107S.
9. Sjogren MH, Sjogren R, Holtzmuller K, Winston B, Butterfield B, Drake S, et al. Interferon alfacon-1 and riba-virin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 2005;50:727-32.
10. Suzuki H, Tango T. A multicenter, randomized, controlled clinical trial of interferon alfacon-1 in comparison with lym-phoblastoid interferon-alpha in patients with high-titer chronic hepatitis C virus infection. Hepatol Res 2002;22: 1-12.
11. Tong MJ, Blatt LM, Resser KJ, Klein MC, Cruickshank SE, Figueroa T, et al. Treatment of chronic hepatitis C virus infection with recombinant consensus interferon. J Interferon Cytokine Res 1998;18:81-6.
12. Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997; 26:747-54.
13. National Institutes of Health Consensus Development Con-ference Panel statement: management of hepatitis C. Hepa-tology 1997;26:2S-10S.
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales Jr FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N EnglJ Med 2002;347: 975-82.
15. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
16. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73:673-9.
17. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, Hasegawa A, et al. Significance of specific anti-body assay for genotyping of hepatitis C virus. Hepatology 1994;19:1347-53.
18. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997;113: 558-66.
19. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
20. Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006;44: 1598-1606.
21. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999;30:1318-24.
22. Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin com-bination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
23. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
24. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previ-ously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
25. Arias E. United States life tables, 2006. Natl Vital Stat Rep 2010;58:1-40.
26. Gold MR, Siegel JE, Russell LB, Weinstein MC Cost-effec-tiveness in health and medicine. New York: Oxford Univer-sity Press; 1996.
27. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997;127: 855-65.
28. Singer ME, Younossi ZM. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. Am J Med 2001;111:667-8.
29. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088-93.
30. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastro-enterol 2001;96:579-83.
31. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98: 630-8.
32. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginter-feron alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32.
33. Suzuki H, Iino S, Omata M, Kumada H, Hino K. Efficacy of interferon alfacon-1 daily induction therapy followed by three-times weekly therapy in patients with chronic hepatitis C virus infection with high and low viral titers. Hepatol Res 1999;15:64-79.
34. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352: 1426-32
35. National Institutes of Health Consensus Development Con-ference Statement: Management of hepatitis C 2002 (10-12 June 2002). Gastroenterology 2002;123:2082-99.
36. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
37. Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43:54-63.
38. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
39. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997;127:866-74.
40. Krahn M, Wong JB, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making 2004;24:20-9.
41. Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. Hepatology 1994;20:24S-27S.
42. Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996;2: 219-28.
43. Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993;56:554-61.
44. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004;10:908-10.
45. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N EnglJ Med 1991;325:729-31.
46. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;329:1896-7.